| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00259-011-2028-1 |
| P698 | PubMed publication ID | 22388629 |
| P2093 | author name string | H Kessler | |
| A J Beer | |||
| M Schwaiger | |||
| F C Gaertner | |||
| H-J Wester | |||
| P2860 | cites work | Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD | Q24805375 |
| Tumor angiogenesis: therapeutic implications | Q27860595 | ||
| Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts | Q28216709 | ||
| Cellular adhesion pathways and metastatic potential of human melanoma | Q28218751 | ||
| New perspectives in cell adhesion: RGD and integrins | Q28280381 | ||
| Angiogenesis in cancer, vascular, rheumatoid and other disease | Q29547165 | ||
| Integrins in cancer: biological implications and therapeutic opportunities | Q29614536 | ||
| Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer | Q29622818 | ||
| 18F-labeled galacto and PEGylated RGD dimers for PET imaging of αvβ3 integrin expression | Q30497615 | ||
| Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. | Q32053981 | ||
| Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. | Q33375093 | ||
| Integrins as "functional hubs" in the regulation of pathological angiogenesis | Q33591910 | ||
| Integrins in vascular development. | Q33690797 | ||
| Cell adhesion molecules in the development and progression of malignant melanoma | Q33865620 | ||
| Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. | Q34159304 | ||
| 18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of alphavbeta3 integrin expression. | Q34205400 | ||
| microPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4) | Q34282774 | ||
| Cancer without disease. | Q34301350 | ||
| Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. | Q35012766 | ||
| Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels | Q35062113 | ||
| Imaging tumour angiogenesis | Q35172997 | ||
| Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells | Q35234791 | ||
| Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation | Q35701298 | ||
| Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin | Q35764323 | ||
| Antivascular cancer treatments: imaging biomarkers in pharmaceutical drug development | Q35905013 | ||
| Instrumentation for molecular imaging in preclinical research: Micro-PET and Micro-SPECT. | Q36341230 | ||
| The integrins | Q36837362 | ||
| Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers | Q37178786 | ||
| Multimodality molecular imaging of tumor angiogenesis | Q37181539 | ||
| Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives | Q37257444 | ||
| Peptide-receptor radionuclide therapy for endocrine tumors | Q37504690 | ||
| Vascular endothelial cell growth factor (VEGF) produced by A-431 human epidermoid carcinoma cells and identification of VEGF membrane binding sites | Q37541880 | ||
| Important role of integrins in the cancer biology | Q37683567 | ||
| [68Ga]NODAGA-RGD for imaging αvβ3 integrin expression. | Q39559499 | ||
| Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αVbeta3-integrin and αV beta5-integrin imaging agent. | Q39592152 | ||
| Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib | Q39868638 | ||
| (68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging | Q39892388 | ||
| (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression | Q40118679 | ||
| Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature | Q41822458 | ||
| The 68Ge/ 68Ga generator has high potential, but when can we use 68Ga-labelled tracers in clinical routine? | Q42594589 | ||
| Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography | Q43561095 | ||
| Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients | Q43788666 | ||
| Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. | Q44203808 | ||
| Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. | Q44275821 | ||
| MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide | Q44735123 | ||
| [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates | Q44735126 | ||
| Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography | Q44996376 | ||
| Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide | Q45008593 | ||
| MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides | Q45068701 | ||
| Imaging of delayed-type hypersensitivity reaction by PET and 18F-galacto-RGD. | Q45211533 | ||
| 18F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer: analysis of a multicenter study. | Q45254019 | ||
| Noninvasive imaging of tumor integrin expression using (18)F-labeled RGD dimer peptide with PEG (4) linkers | Q46083932 | ||
| microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide | Q46115376 | ||
| Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy | Q46192839 | ||
| The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers | Q46365501 | ||
| Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide targeted at alphavbeta3 integrin after murine hindlimb ischemia | Q46547003 | ||
| Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients | Q46639250 | ||
| Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice | Q46643953 | ||
| Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. | Q46805017 | ||
| Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. | Q46852304 | ||
| [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck | Q46897615 | ||
| Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide | Q48349734 | ||
| An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the alpha v beta 3-selective angiogenesis imaging agent 99mTc-NC100692. | Q48382974 | ||
| Performance characteristics of a new 3-dimensional continuous-emission and spiral-transmission high-sensitivity and high-resolution PET camera evaluated with the NEMA NU 2-2001 standard. | Q51294264 | ||
| Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. | Q51653388 | ||
| Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone. | Q52536880 | ||
| [Molecular imaging with new PET tracers]. | Q53510437 | ||
| Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. | Q53530857 | ||
| PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. | Q53540557 | ||
| Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. | Q53686513 | ||
| Angiogenesis | Q56689455 | ||
| Integrin alpha V beta 3 expression by bone-residing breast cancer metastases | Q71312522 | ||
| 18F-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer | Q79867091 | ||
| Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692 | Q80216849 | ||
| Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme | Q81615619 | ||
| TRAP, a powerful and versatile framework for gallium-68 radiopharmaceuticals | Q82836384 | ||
| Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007 | Q83206208 | ||
| P304 | page(s) | S126-38 | |
| P577 | publication date | 2012-02-01 | |
| P1433 | published in | European Journal of Nuclear Medicine and Molecular Imaging | Q15708890 |
| P1476 | title | Radiolabelled RGD peptides for imaging and therapy | |
| P478 | volume | 39 Suppl 1 |
| Q35888323 | (99m)Tc-3P-RGD2 molecular imaging targeting integrin α v β 3 in head and neck squamous cancer xenograft |
| Q39432870 | 18 F-Labeling of Sensitive Biomolecules for Positron Emission Tomography. |
| Q64980444 | 64Cu-Labeled Phosphonate Cross-Bridged Chelator Conjugates of c(RGDyK) for PET/CT Imaging of Osteolytic Bone Metastases. |
| Q57059501 | 99mTc-3PRGD2 single-photon emission computed tomography/computed tomography for the diagnosis of choroidal melanoma: A preliminary STROBE-compliant observational study |
| Q43376041 | A First Report on [18F]FPRGD2 PET/CT Imaging in Multiple Myeloma |
| Q51395181 | A novel Tc-99 m and fluorescence labeled peptide as a multimodal imaging agent for targeting angiogenesis in a murine tumor model. |
| Q43821024 | A practical synthesis of [(18) F]FtRGD: an angiogenesis biomarker for PET. |
| Q59808413 | A study on screening and antitumor effect of CD55-specific ligand peptide in cervical cancer cells |
| Q38878464 | An integrin-targeted photoactivatable Pt(IV) complex as a selective anticancer pro-drug: synthesis and photoactivation studies |
| Q37558860 | Anti-tumor effect of integrin targeted (177)Lu-3PRGD2 and combined therapy with Endostar |
| Q48294611 | Automated preparation of 2-[18 F]fluoropropionate labeled peptides using a flexible, multi-stage synthesis platform (iPHASE Flexlab). |
| Q57093159 | Biodistribution and Internal Radiation Dosimetry of Tc-IDA-D-[c(RGDfK)] (BIK-505), a Novel SPECT Radiotracer for the Imaging of Integrin αβ Expression |
| Q26771417 | Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin αvβ3 |
| Q55387769 | Comparison and evaluation of two RGD peptides labelled with 68Ga or 18F for PET imaging of angiogenesis in animal models of human glioblastoma or lung carcinoma. |
| Q37230541 | Comparison of Ga-68-Labeled Fusarinine C-Based Multivalent RGD Conjugates and [(68)Ga]NODAGA-RGD-In Vivo Imaging Studies in Human Xenograft Tumors |
| Q40858096 | Comparison of cyclic RGD peptides for αvβ3 integrin detection in a rat model of myocardial infarction |
| Q52708818 | Conjugates of Cell Adhesion Peptides for Therapeutics and Diagnostics Against Cancer and Autoimmune Diseases. |
| Q38717786 | Construction and Biological Evaluation of a Novel Integrin ανβ₃-Specific Carrier for Targeted siRNA Delivery In Vitro. |
| Q34162650 | Cyclic RGD Peptides Incorporating Cycloalkanes: Synthesis and Evaluation as PET Radiotracers for Tumor Imaging |
| Q38137253 | Design and evaluation of radiolabeled tracers for tumor imaging |
| Q34724473 | Development of a new positron emission tomography tracer for targeting tumor angiogenesis: synthesis, small animal imaging, and radiation dosimetry. |
| Q33686825 | Dimerization of a phage-display selected peptide for imaging of αvβ6- integrin: two approaches to the multivalent effect. |
| Q34216798 | Dynamic PET and SPECT imaging with radioiodinated, amyloid-reactive peptide p5 in mice: a positive role for peptide dehalogenation. |
| Q35688211 | Efficient Identification of Murine M2 Macrophage Peptide Targeting Ligands by Phage Display and Next-Generation Sequencing |
| Q90703406 | Evaluation of integrin αvβ6 cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis |
| Q36113183 | Evaluation of two novel ⁶⁴Cu-labeled RGD peptide radiotracers for enhanced PET imaging of tumor integrin αvβ₃. |
| Q35760732 | Exploration of peptide T7 and its derivative as integrin αvβ3-targeted imaging agents |
| Q34556242 | FITC-conjugated cyclic RGD peptides as fluorescent probes for staining integrin αvβ3/αvβ5 in tumor tissues |
| Q51750828 | Fast and efficient (18) F-labeling by [(18) f]fluorophenylazocarboxylic esters. |
| Q49158345 | Feasibility of [18F]-RGD for ex vivo imaging of atherosclerosis in detection of αvβ3 integrin expression |
| Q35589741 | First-In-Human Study Demonstrating Tumor-Angiogenesis by PET/CT Imaging with (68)Ga-NODAGA-THERANOST, a High-Affinity Peptidomimetic for αvβ3 Integrin Receptor Targeting |
| Q40832534 | Functional Cell Adhesion Receptors (Integrins) in Polymeric Architectures |
| Q38942329 | H-CRRETAWAC-OH, a lead structure for the development of radiotracer targeting integrin α5β1? |
| Q94556014 | Head and neck tumors angiogenesis imaging with 68Ga-NODAGA-RGD in comparison to 18F-FDG PET/CT: a pilot study |
| Q36287535 | Heat-induced-radiolabeling and click chemistry: A powerful combination for generating multifunctional nanomaterials |
| Q35602386 | Hollow mesoporous silica nanoparticles for tumor vasculature targeting and PET image-guided drug delivery |
| Q30432014 | Image-guided cancer surgery using near-infrared fluorescence |
| Q42602933 | Imaging of Integrin αvβ3 Expression in Lung Cancers and Brain Tumors Using Single-Photon Emission Computed Tomography with a Novel Radiotracer 99mTc-IDA-D-[c(RGDfK)]2 |
| Q26798266 | Imaging radiation response in tumor and normal tissue |
| Q38700087 | Integrin Ligands with α/β-Hybrid Peptide Structure: Design, Bioactivity, and Conformational Aspects |
| Q37236103 | Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics |
| Q51751868 | Longitudinal monitoring of tumor antiangiogenic therapy with near-infrared fluorophore-labeled agents targeted to integrin αvβ3 and vascular endothelial growth factor. |
| Q38929240 | MicroPET imaging of tumor angiogenesis and monitoring on antiangiogenic therapy with an (18)F labeled RGD-based probe in SKOV-3 xenograft-bearing mice |
| Q50993912 | MicroPET/CT imaging of αvβ₃ integrin via a novel ⁶⁸Ga-NOTA-RGD peptidomimetic conjugate in rat myocardial infarction. |
| Q28073273 | Molecular Imaging of Angiogenesis in Cardiac Regeneration |
| Q38169570 | Molecular imaging agents for SPECT (and SPECT/CT). |
| Q60923329 | Multimodal and Multiscale Analysis Reveals Distinct Vascular, Metabolic and Inflammatory Components of the Tissue Response to Limb Ischemia |
| Q42801541 | Multivalency Increases the Binding Strength of RGD Peptidomimetic-Paclitaxel Conjugates to Integrin αV β3. |
| Q41354108 | Non-invasive assessment of inter-and intrapatient variability of integrin expression in metastasized prostate cancer by PET. |
| Q48258100 | Noninvasive imaging of c(RGD)2 -9R as a potential delivery carrier for transfection of siRNA in malignant tumors. |
| Q35676322 | Novel Bifunctional Cyclic Chelator for (89)Zr Labeling-Radiolabeling and Targeting Properties of RGD Conjugates |
| Q35882341 | Optimization of RGD-Containing Cyclic Peptides against αvβ3 Integrin |
| Q47868574 | PET and SPECT imaging of melanoma: the state of the art. |
| Q53060216 | PET imaging of cardiac wound healing using a novel [68Ga]-labeled NGR probe in rat myocardial infarction. |
| Q36997603 | PET imaging of inflammation biomarkers |
| Q38444980 | PET in the management of locally advanced and metastatic NSCLC. |
| Q38228356 | PET radiopharmaceuticals for imaging integrin expression: tracers in clinical studies and recent developments. |
| Q33665109 | PET/CT in Oncology: Current Status and Perspectives |
| Q37585965 | Peptide-based imaging agents for cancer detection |
| Q38112578 | Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example. |
| Q38166986 | RGD-based PET tracers for imaging receptor integrin αv β3 expression |
| Q38732486 | RGD-mediated delivery of small-molecule drugs. |
| Q26801806 | Radiolabeled Cyclic RGD Peptide Bioconjugates as Radiotracers Targeting Multiple Integrins |
| Q39047828 | Radiolabeled RGD tracer kinetics annotates differential αvβ 3 integrin expression linked to cell intrinsic and vessel expression |
| Q28072021 | Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging |
| Q38755295 | Radiolabelled Polymeric Materials for Imaging and Treatment of Cancer: Quo Vadis? |
| Q30577193 | Radiolabelled probes for imaging of atherosclerotic plaques. |
| Q99628392 | Research Progress of Radiolabeled Asn-Gly-Arg (NGR) Peptides for Imaging and Therapy |
| Q35796600 | SPECT/CT Imaging of High-Risk Atherosclerotic Plaques using Integrin-Binding RGD Dimer Peptides. |
| Q51060448 | Synthesis and preliminary biological evaluation of a 99m Tc-chlorambucil derivative as a potential tumor imaging agent. |
| Q53074894 | Synthesis of a non-peptidic PET tracer designed for α5β1 integrin receptor. |
| Q41949498 | Synthesis, Chemical Characterization and Multiscale Biological Evaluation of a Dimeric-cRGD Peptide for Targeted Imaging of α V β 3 Integrin Activity |
| Q39129886 | Targeted delivery of antisense oligonucleotides by chemically self-assembled nanostructures. |
| Q37317221 | The feasibility of 18F-AlF-NOTA-PRGD2 PET/CT for monitoring early response of Endostar antiangiogenic therapy in human nasopharyngeal carcinoma xenograft model compared with 18F-FDG. |
| Q100751715 | Toward diagnostic relevance of the αVβ5, αVβ3, and αVβ6 integrins in OA: expression within human cartilage and spinal osteophytes |
| Q58728351 | Translational molecular imaging in exocrine pancreatic cancer |
| Q38100112 | Tumour targeting with radiometals for diagnosis and therapy |
| Q54240716 | Use of a leukocyte-targeted peptide probe as a potential tracer for imaging the tuberculosis granuloma. |
| Q44462472 | Using 5-deoxy-5-[18F]fluororibose to glycosylate peptides for positron emission tomography |
| Q38933775 | [(68)Ga]FSC-(RGD)3 a trimeric RGD peptide for imaging αvβ3 integrin expression based on a novel siderophore derived chelating scaffold-synthesis and evaluation |
| Q52944077 | [PET-CT in head and neck cancer]. |
| Q45287510 | [¹⁸F]fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing αvβ 3 and α vβ 5 integrins. |
| Q52926003 | ¹⁸F-FPRGD₂ PET/CT imaging of musculoskeletal disorders. |
Search more.